Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Explore our online Annual Report 2024 summary Discover how we champion inclusion and diversity at AstraZeneca We have 191 projects in our pipeline View pipeline Learn about our cell therapy ambition ...
AstraZeneca Annual Report 2023. Available at:https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2023/pdf/AstraZeneca_AR_2023.pdf. [Last accessed:April 2024]. AstraZeneca plc. FY and Q4 2023 Results. Conference call and webcast for investors and analysts. Availabl...
According to AstraZeneca’s 2023 annual report, Tagrisso, a lung cancer treatment approved in 101 countries, generated $5.8 billion in revenue, followed by Imfinzi, another drug for lung cancer, which brought in $4.2 billion. The company generated about 13% of its global revenue from China las...
described in the forward-looking statements can be found in AstraZeneca’s Annual Report on Form 20 F for the year ended 31st December 2023 and Fusion’s Annual Report on Form 10 K for the year ended 31st December 2023, in each case as amended by any...
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AstraZeneca’s Annual Report on Form 20-F for the year ended 31 December 2022 and Gracell’s Annual Report on Form 20-F for the...
Learn more about past programs. Annual Reports 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Special Report Helping to Improve Heart Health: Reflections from a 10-Year Journey Latest AstraZeneca Foundation News Latest Search Clear search More filters Less filters Filters Appl...
This data builds upon TROPION-Lung01 results presented at the 2023 European Society for Medical Oncology Congress, which showed a clinically significant increase in progression-free survival with datopotamab deruxtecan versus docetaxel for nonsquamous NSCLC patients. Entering into collaboration in July...
SG&A decreased to 28% of total revenue on a full-year basis. Other operating income declined significantly as we booked more than $700 million in 2023 relating to the update of the contractual agreement on Beyfortus, as well as $250 million relating to the U.S. divestment of Pulmicort. ...
9 November 2023 In-line Q3; strong operational performance prompts outlook upgrade The Q3 results were in line with the consensus and AV’s estimates and, given the strong momentum acr... View report Load more Latest reportsfrom AstraZeneca Plc View all our reports AstraZeneca Annual Reports ...
Calquence’s new FDA approval makes it the first BTK inhibitor approved as a first-line MCL treatment. That gives the drug an edge over others in its class. Eli Lilly’s BTK inhibitor, Jaypirca, landedFDA approval in 2023as a third-line treatment for MCL. Imbruvica, marketed b...